To include your compound in the COVID-19 Resource Center, submit it here.

BIO's warning on Hatch-Waxman reform

The White House is not only firmly opposed to reimportation, but it also warned the Senate that it isn't any more enthusiastic about bipartisan proposals for reforming the Hatch-Waxman Act. The act facilitates the marketing of generic versions of drugs as soon as patents expire and provides

Read the full 470 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers